Imaging active blood clots using PET technology

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to improve the diagnostic accuracy of venous thromboembolism (VTE), which includes conditions like deep vein thrombosis and pulmonary embolism. It focuses on utilizing positron emission tomography (PET) to visualize active venous thrombi directly, contrasting with traditional imaging techniques that only show the effects of obstructions. By marking the thrombus, the study seeks to better identify patients who require anticoagulant treatment and avoid unnecessary long-term therapy for those who do not. The approach involves additional blood sampling to enhance the imaging process.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Major patient (≥18 years), voluntary blood donor, with no notable medical history altering coagulation (i.e. known thrombophilia, active cancer), no chronic pathology, no current treatment.

Exclusion Criteria:

Minor patient (\<18 years); known chronic pathology; long-term treatment including anti-platelet aggregation therapy or anticoagulant treatment, refusal to participate.

Where it's running

• Etablissement francais du sang
  Brest, France Recruiting

Study contacts

• Study coordinator: Philippe ROBIN
• Email: philippe.robin@chu-brest.fr
• Phone: +33(0)298223327

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Aspirin vs. rivaroxaban for blood clot prevention in newly diagnosed multiple myeloma

  In newly diagnosed multiple myeloma patients on IMiD-based therapy, this study tests whether aspirin or rivaroxaban is better at preventing blood clots.

  Recruiting Phase 4 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07907211

• TRiP-cast score test in adults with acute lower-limb injuries requiring immobilization

  This study tests whether the TRiP(cast) score can predict risk of blood clots in adults with acute lower-limb injuries treated as outpatients.

  Recruiting University of Monastir · Monastir · NCT07863115

• Pulmonary Embolism Registry from Emergency Care to Long-Term Follow-Up

  This registry follows adults with acute pulmonary embolism to see how care is given in the real world and what happens over time.

  Recruiting at 16 sites Azienda Ospedaliero-Universitaria Careggi · Bagno a Ripoli, Tuscany and 15 other locations · NCT07855679

• YKYY033 Injection safety and tolerability in adults

  This study tests whether a single dose of YKYY033 injection is safe and tolerable in healthy adults aged 18–55.

  Recruiting Phase 1 Youcare Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality · NCT07786779

• Blood-clot prevention with REGN7508 and REGN9933 in people with PICC lines

  This study tests whether REGN7508 and REGN9933 can help prevent blood clots in people who have a PICC line.

  Recruiting Phase 3 Regeneron Pharmaceuticals · Tbilisi · NCT07697599

• Treatment and prevention of blood clots in adults with cancer

  This study tests REGN7508 against apixaban to see if it can treat and prevent blood clots in adults with or without cancer, including those with cancer-related clots in the legs and lungs.

  Recruiting at 12 sites Phase 3 Regeneron Pharmaceuticals · Hialeah, Florida and 13 other locations · NCT07493304

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.